Literature DB >> 30188790

Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate.

F J Sherida H Woei-A-Jin1, Tine Van Nieuwenhuyse1, Nielka P van Erp1, Benoit Beuselinck1, Stephanie Stroobants1, Dirk Jan A R Moes1, Susanne Osanto1, Isabel Spriet1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30188790     DOI： 10.1200/JCO.2018.79.3182

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  1 in total

1.  AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.

Authors:  Rafael Adrián Pacheco-Orozco; Lorena Montealegre-Páez; Federico Cayol; Héctor Martínez-Gregorio; Javier Oliver; Cecilia Frecha; Felipe Vaca-Paniagua; Sandra Perdomo
Journal:  Oncologist       Date:  2020-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.